Here’s what most pharma market access teams discover too late: clinical trial data tells you what can happen under perfect conditions. Aggregated health insurance claims data shows you what actually happens when patients fill prescriptions at their local pharmacy, switch therapies because of tolerability issues, or stop treatment altogether after three months.
The gap between these two realities? That’s where your launch forecasts fall apart, your HEOR submissions lack credibility, and your competitive positioning misses the mark.
In my experience advising pharmaceutical companies across Continental Europe and beyond, the ones who understand real-world treatment pathways—the actual sequences of therapies, switching patterns, and persistence rates happening in everyday clinical practice—are the ones who get market access right, size opportunities accurately, and build patient support programs that actually work.
Why Clinical Trials Can’t Tell You Everything About Treatment Pathways
Clinical trials are designed for one thing: demonstrating efficacy and safety under controlled conditions. They’re brilliant at that. But they’re terrible at predicting what happens when your product enters the messy reality of clinical practice.
Think about it. In a randomized controlled trial, patients are carefully selected. Adherence is monitored constantly. There’s no competition from other therapies unless you’re running a head-to-head study. Payer restrictions don’t exist. And patients certainly don’t stop taking their medication because they forgot to refill it or couldn’t afford the copay.
Real-world evidence from aggregated claims data reveals the uncomfortable truths trials can’t capture:
Persistence rates drop dramatically. That 85% treatment continuation rate at 12 months in your Phase III trial? In claims data analysis, we routinely see 40-50% discontinuation by month six for chronic therapies. Patients stop refilling. They switch to competitors. They abandon treatment entirely.
Treatment sequences rarely follow guidelines. Professional societies publish beautiful treatment algorithms showing first-line, second-line, and third-line therapies. Claims data shows physicians prescribing all over the map—sometimes skipping lines entirely, sometimes combining therapies in unexpected ways, sometimes reverting to older treatments after newer ones fail.
Switching patterns tell the real competitive story. You might have superiority data versus Competitor A in a head-to-head trial. But if claims data shows 30% of your patients switching to Competitor A within the first year while only 15% switch from A to you, there’s a tolerability or formulary issue your trial didn’t capture.
According to research published in Value in Health, real-world data studies are now essential for understanding treatment effectiveness beyond the artificial constraints of RCTs. The FDA has been increasingly clear about this—their Framework for Real-World Evidence explicitly recognizes that administrative claims databases provide critical insights into actual treatment patterns and patient outcomes.
What Makes Aggregated Health Insurance Claims Data the Gold Standard
When pharmaceutical companies need to understand treatment pathways at scale, they turn to aggregated health insurance claims data. Not patient surveys. Not physician panels. Not even electronic health records (though EHRs complement claims beautifully when linked together).
Why? Because claims data captures the one thing that matters most: what medications were actually dispensed and paid for.
Every time a patient fills a prescription at a pharmacy, a claim gets submitted to their health insurer. That claim includes the medication (identified by ATC code or NDC), the quantity dispensed, the date, and crucially—whether it was filled again. String these refill events together across months and years, and you’ve got a longitudinal treatment pathway.
The strengths are undeniable. Claims databases from major providers cover millions of patients—across Continental Europe, comprehensive coverage spans statutory and private insurance systems. The data is objective… there’s no recall bias like you’d get asking physicians what they prescribed six months ago. And it’s already structured for analysis—diagnosis codes (ICD-10), procedure codes, and medication codes (ATC classification) make it straightforward to identify patient cohorts and track their treatment journeys.
Compare this to other real-world data sources. Electronic health records provide rich clinical detail—lab values, physician notes, symptoms—but they’re fragmented across healthcare systems and often incomplete when it comes to filled prescriptions. Disease registries offer high-quality outcomes data for specific conditions, but they’re limited to small, highly selected populations. Patient-reported outcomes capture the patient experience, but they’re subjective and labor-intensive to collect.
For treatment pathway analysis specifically, claims data dominates because it excels at the metrics that matter:
Treatment sequencing: First-line, second-line, third-line—claims data maps the actual sequence of therapies dispensed over time. You can see exactly which medications patients tried before landing on your product (or which ones they switched to after leaving it).
Therapy switching: When patients switch from one medication to another, the claims trail shows it clearly. You can quantify switch rates, identify common switch patterns (brand to generic, within-class switching, cross-class switching), and calculate time to switch.
Persistence and adherence: Refill patterns tell you how long patients stay on therapy (persistence) and how consistently they refill prescriptions (adherence). Metrics like proportion of days covered (PDC) and medication possession ratio (MPR) derive directly from dispensing records—no patient questionnaires required.
The FDA’s 2023 guidance on using medical claims data for regulatory decisions acknowledges these advantages explicitly. When designed properly, claims-based studies can support drug approvals, label expansions, and post-marketing surveillance.
Critical Applications: How Pharma Companies Actually Use Treatment Pathway Data
Let me walk you through how this works in practice across different functions within pharmaceutical and MedTech organizations.
Market Access Teams Need Real-World Treatment Sequences for HEOR Dossiers
Your market access team is preparing an HTA dossier for NICE in the UK or a reimbursement submission in France. The payer asks: “Where does your product fit in the treatment pathway? What’s the comparative effectiveness versus existing options? What’s the budget impact if we reimburse this?”
Clinical trial data gives you the efficacy story. Claims data gives you the utilization story that actually drives budget impact.
Using aggregated claims databases, you can show payers exactly how patients currently navigate treatment—what percentage receive first-line therapy, how many progress to second-line, what the average time to treatment escalation looks like, and where patients are getting stuck or undertreated. Then you can model where your product fits, demonstrate its value in the context of actual prescribing patterns, and provide credible forecasts of uptake and switching.
Research in Advances in Therapy has demonstrated that real-world clinical data—including claims-based pathway analyses—significantly impacts clinical decision-making when presented with proper context. Payers trust this data because it reflects their own population’s behavior.
The challenge most companies face isn’t finding claims data providers—it’s determining which combination of coverage, analytical capabilities, and domain expertise aligns with their strategic priorities for a specific HTA submission.
Commercial Analytics Teams Optimize Launch Strategy and Competitive Intelligence
You’re launching a new oncology therapy. Your commercial team needs to forecast uptake, identify early adopter physicians, and understand competitive vulnerabilities.
Claims-based treatment pathway analysis tells you precisely where your competitors are strong and where they’re vulnerable. If Competitor A has 60% market share in first-line but only 20% in second-line, that’s actionable intelligence. If persistence on Competitor B drops sharply after six months, you can position your product’s tolerability advantage specifically to prescribers frustrated with B’s discontinuation rates.
You can also size your opportunity accurately. Instead of guessing how many patients might be eligible for your therapy based on prevalence estimates, you can see exactly how many patients in claims data received therapies in the relevant treatment line over the past year—and model your peak share based on similar product launches in the data.
Understanding which data sources provide the geographic granularity, therapeutic depth, and recency you need for competitive intelligence requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem.
Medical Affairs and HEOR Teams Build Evidence for Comparative Effectiveness
Increasingly, pharma companies need comparative effectiveness research that goes beyond head-to-head trials (which are expensive and often unfeasible). Claims data enables indirect comparisons using real-world populations.
For example, a claims-based analysis of psoriasis biologics published in the Journal of Dermatological Treatment mapped treatment patterns, adherence, and persistence across multiple therapies—providing comparative insights without requiring a single head-to-head RCT. This type of evidence supports medical affairs conversations, publication strategies, and payer negotiations.
Real-world persistence data is particularly valuable. A study in ACR Open Rheumatology examining rheumatoid arthritis treatment patterns used claims data to demonstrate significant differences in persistence between first-line TNF inhibitors—evidence that directly informed formulary decisions and treatment guidelines.
Clinical Development Teams Identify Unmet Needs and Optimize Trial Design
Before initiating Phase II trials, smart clinical teams analyze claims data to understand current treatment gaps. Are patients with certain comorbidity profiles undertreated? Do existing therapies show poor persistence in specific subpopulations? Where are physicians cycling through multiple failed therapies?
These insights shape trial inclusion criteria, endpoint selection, and even indication strategy. If claims data reveals that 40% of patients discontinue standard-of-care within three months, you might design your trial to demonstrate superior persistence at that timepoint—making your results directly relevant to payer concerns.
Claims data can also identify potential trial sites by showing which physician practices or healthcare systems treat high volumes of your target population, improving recruitment efficiency.
A Real-World Example: Pulmonary Arterial Hypertension Treatment Pathways
Let me make this concrete with pulmonary arterial hypertension (PAH)—a rare, progressive disease where treatment pathway analysis has proven particularly valuable.
PAH treatment guidelines from the European Society of Cardiology and European Respiratory Society recommend risk-stratified approaches with multiple therapy classes: endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5i), prostacyclin analogs, and newer agents like soluble guanylate cyclase stimulators.
But what actually happens in practice?
Claims-based studies like the one published in Annals of the American Thoracic Society have shown how to identify PAH patients in administrative claims using diagnosis code algorithms and medication fills. Once identified, researchers can track treatment sequences from diagnosis forward.
A subsequent analysis in Pulmonary Circulation examining real-world PAH treatment patterns revealed that many patients remain on monotherapy longer than guidelines suggest, combination therapy uptake varies dramatically by region, and persistence on parenteral prostacyclin therapy is lower than expected—requiring frequent switches or discontinuations.
For a pharmaceutical company with a PAH product, this intelligence is invaluable. It identifies where current therapies fall short (poor persistence), where guidelines aren’t being followed (delayed combination therapy), and where market access barriers exist (regional variation suggesting payer restrictions). Each insight translates directly into positioning strategy, medical education priorities, and evidence generation plans.
Key Metrics You Can Extract from Claims-Based Pathway Analysis
When you’re analyzing treatment pathways using aggregated claims data, here are the specific metrics pharmaceutical teams extract:
Treatment sequence metrics. Percentage of patients receiving first-line, second-line, third-line therapy. Time from diagnosis to treatment initiation. Time between treatment lines. Most common therapy sequences (e.g., “First-line methotrexate → Second-line TNF inhibitor → Third-line JAK inhibitor”).
Switching metrics. Switch rates by timepoint (6-month switch rate, 12-month switch rate). Switch patterns (which therapies patients switch from and to). Reasons for switching (inferred from add-on medications or adverse event codes appearing before switches). Time to switch.
Persistence metrics. Median time on therapy. Kaplan-Meier curves showing treatment discontinuation over time. Percentage persisting at 6 months, 12 months, 24 months. Comparison of persistence across therapies within the same class.
Adherence metrics. Proportion of days covered (PDC) — the percentage of days in an observation period where the patient has medication available based on refills. Medication possession ratio (MPR) — ratio of days’ supply obtained to days in period. Percentage of patients considered adherent (typically PDC ≥ 80%).
Utilization metrics. Concomitant medication use (what else patients take alongside your therapy). Healthcare resource utilization (hospitalizations, ER visits, specialist visits) during treatment. Dose escalation or de-escalation patterns.
Patient journey metrics. Complete pathway from diagnosis through multiple treatment lines. Comorbidity burden at each stage. Time to key outcomes (inferred from claims—e.g., hospitalization for disease complication). Gaps in care (periods without expected monitoring or treatment).
These metrics require careful epidemiologic design. As detailed in the ISPOR-ISPE joint task force recommendations for real-world evidence studies, claims-based analyses must account for biases like immortal time bias, confounding by indication, and differential follow-up.
Understanding Your Options: What to Look For in Claims Data Capabilities
The claims data landscape includes dozens of providers with overlapping but distinct capabilities. Understanding which combination matches your specific needs requires evaluating several critical dimensions:
Coverage and Geographic Scope
Coverage breadth varies dramatically. Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater therapeutic depth.
For Continental European applications, you’ll find providers specializing in pan-European statutory and private insurance data, while others focus on individual markets with deeper regional granularity. The choice depends on whether you need broad European insights or detailed market-specific intelligence.
Critical questions: Does the coverage include your target therapeutic areas at sufficient scale? Are patient populations representative of your commercial opportunity? Does geographic granularity match your market access strategy?
Data Recency and Update Frequency
Timeliness varies significantly. Some sources provide near-real-time data with monthly updates, enabling rapid competitive intelligence and launch tracking. Others work with adjudicated claims that lag 6-12 months but offer greater completeness and accuracy.
For market sizing and forecasting, recent data is critical. For regulatory submissions requiring validated cohorts, adjudicated claims with complete follow-up may be preferable despite the lag.
Analytical Capabilities and Access Models
Analytical sophistication represents a major point of differentiation. Some providers offer self-service query platforms where your data science team can run custom analyses. Others provide full-service research support where their epidemiologists design and execute studies on your behalf.
Advanced capabilities include AI-powered platforms for real-time pattern recognition, predictive analytics for forecasting patient journeys, and natural language processing for extracting insights from unstructured data. The choice depends on your internal analytical capabilities and the complexity of your research questions.
Data Integration and Linkage
Some sources combine claims with complementary data—lab results, specialty pharmacy records, provider characteristics, social determinants of health—creating richer patient profiles. This vertical integration enables analyses that pure claims data cannot support, such as correlating treatment persistence with clinical biomarkers or socioeconomic factors.
Linkage methodologies also vary. Sophisticated probabilistic matching can track patients across payers and care settings, while simpler approaches may lose patients who switch insurance or move geographically.
Compliance and Data Quality Standards
GDPR compliance is non-negotiable for European applications. Providers use various anonymization techniques—generalization, suppression, synthetic data generation using GANs—to enable analysis while preserving privacy. The sophistication of these approaches affects both compliance risk and analytical flexibility.
Data quality processes also differ. Look for providers with validated algorithms for identifying disease cohorts (published positive predictive values), rigorous data cleaning protocols, and transparent documentation of coverage gaps or data limitations.
Navigating this landscape requires expertise in both pharmaceutical strategy and the evolving real-world evidence ecosystem. The gap between understanding what claims data can do and identifying which specific capabilities match your needs is where expert guidance becomes critical.
Advanced Analytics: AI and Machine Learning for Predictive Pathway Modeling
While traditional treatment pathway analysis is descriptive—showing what has happened—pharmaceutical companies are increasingly applying AI and machine learning to claims data for predictive insights.
Sequence mining algorithms can identify previously unrecognized treatment patterns buried in millions of patient records. Researchers examining rheumatoid arthritis pathways in Brazilian claims data used computational approaches to map complex sequential patterns that manual analysis would have missed.
Predictive models can forecast which patients are at high risk of discontinuation, which treatment sequences are associated with better outcomes, and where therapy escalation is likely to occur. As noted in a comprehensive review in Clinical Pharmacology & Therapeutics, AI applications in real-world evidence are transforming how pharmaceutical companies use claims data—moving from retrospective description to prospective optimization.
These advanced analytics require high-quality, analysis-ready datasets. Raw claims data is notoriously messy—inconsistent coding, billing errors, missing fields. The value of working with experienced providers is that they’ve already done the heavy data engineering: standardized codes across years, linked patient records longitudinally, removed duplicates, validated diagnosis-procedure-medication coherence.
The time-to-insight difference between analysis-ready data and raw feeds is dramatic—48 hours versus 6-12 months. Understanding which providers offer truly analysis-ready data versus those requiring substantial data engineering investment is a critical evaluation criterion.
Limitations and Complementary Data Sources
For all its strengths, aggregated health insurance claims data has limitations for treatment pathway analysis. It’s important to acknowledge these honestly.
Claims lack clinical detail. You can see that a patient switched from Medication A to Medication B, but claims don’t tell you why. Was it lack of efficacy? Adverse events? Patient preference? Payer restriction? You can infer reasons from patterns (e.g., an adverse event diagnosis code appearing right before a switch), but it’s still inference.
Lab results and biomarkers aren’t captured. Claims show diagnoses and medications, but not the HbA1c level that prompted a diabetes treatment escalation or the viral load that indicated HIV treatment failure. For pathway analyses requiring clinical markers, claims data needs to be linked with EHR data or lab databases.
Over-the-counter medications are invisible. If patients switch from a prescription therapy to an OTC alternative, claims data shows discontinuation but not the OTC use. This particularly affects analyses in categories like pain management or allergy treatment.
Dispensing doesn’t equal consumption. Claims show prescriptions filled, not necessarily medications taken. A patient might fill a prescription but never actually start the medication, or might take it sporadically despite regular refills. Adherence metrics like PDC assume dispensed medications are consumed, which overstates true adherence.
Smart pharma teams address these gaps by combining claims data with complementary sources. Linking claims to EHR data adds clinical depth. Incorporating patient-reported outcomes through surveys adds the patient perspective. Using registry data for rare diseases adds outcome validation. As described in a Pharmaceutical Medicine primer on real-world evidence fundamentals, integrated data strategies that combine claims with other RWD sources deliver the richest insights.
Understanding which data integration approaches serve specific research questions—and which providers offer the necessary linkage capabilities—requires deep knowledge of both the vendor landscape and pharmaceutical research methodology.
Compliance Considerations: GDPR, Anonymization, and Synthetic Data
Using health insurance claims data for treatment pathway analysis requires rigorous compliance with GDPR, particularly Article 9 which governs special category data including health information.
The key principle: aggregated, anonymized claims data that cannot be re-identified to individual patients falls outside GDPR’s strictest requirements. But true anonymization is technically challenging—simply removing names and addresses isn’t sufficient if combinations of rare diagnoses, demographics, and treatment patterns could theoretically re-identify individuals.
This is where modern claims data providers apply sophisticated anonymization techniques: generalization (aggregating geography to regional level rather than postal codes), suppression (removing rare combinations), and increasingly—synthetic data generation.
Synthetic health data, created using machine learning approaches like GANs, maintains the statistical properties and correlational structure of real claims data while containing no actual patient records. This enables complex pathway analyses—including modeling rare treatment sequences or running scenario analyses—without any risk of patient re-identification.
The practical implication: when evaluating claims data partnerships, verify anonymization methodology, GDPR compliance certifications (look for ISO 27001), and ideally—synthetic data capabilities that eliminate residual privacy risks entirely. The sophistication of these approaches varies significantly across providers.
Common Questions Pharma Teams Ask About Claims-Based Pathway Analysis
How quickly can we get insights from claims data?
With analysis-ready claims databases, you can go from research question to initial insights in as little as 48 hours for straightforward queries (e.g., “What percentage of Type 2 diabetes patients start SGLT2 inhibitors as first-line therapy?”). Complex pathway analyses requiring custom cohort definitions, multi-year follow-up, and comparative statistics typically take 2-4 weeks. This is dramatically faster than primary research like physician surveys or chart reviews, which can take 6-12 months.
However, the time-to-insight depends heavily on data readiness. Some providers offer truly analysis-ready platforms where queries can be executed immediately. Others require substantial data engineering before analysis can begin, extending timelines by months.
Can claims data support regulatory submissions?
Yes—increasingly. The FDA’s RWE framework and recent approvals using real-world data demonstrate that well-designed claims-based studies can support label expansions, new indications, and even initial approvals in certain contexts. The EMA similarly accepts real-world evidence for post-authorization safety studies and effectiveness assessments. Key requirements include robust study design, validation of claims-based algorithms for identifying patient cohorts, and appropriate control for confounding.
How do we validate that claims data accurately identifies our target patients?
This requires developing and validating case definitions—specific combinations of diagnosis codes, procedure codes, and medication fills that identify your patient population. Published algorithms exist for many conditions (validated positive predictive values often range from 75-95%). For novel indications or rare diseases, you may need to validate your algorithm against a gold standard dataset like registry data or chart review.
Experienced providers maintain libraries of validated algorithms for common conditions, accelerating this process. Understanding which providers have relevant therapeutic expertise in your disease area is a critical selection criterion.
What’s the difference between claims-based pathway analysis and EHR-based analysis?
Claims data excels at medication dispensing patterns, healthcare utilization, and longitudinal tracking across all providers and settings. EHR data excels at clinical details like lab values, vital signs, and physician notes but is often incomplete for medications (especially those filled at external pharmacies) and fragmented across different healthcare systems. For comprehensive pathway analysis, linked claims-EHR datasets are ideal—claims for longitudinal medication tracking, EHR for clinical context.
Some providers specialize in claims data, others in EHR networks, and a few offer integrated platforms linking both. The choice depends on whether your research questions require clinical depth or can be answered with dispensing patterns and utilization data alone.
How do we handle competing events and censoring in pathway analyses?
This is a critical epidemiologic consideration. Patients may discontinue follow-up (move, switch insurance), die, or experience events that preclude further treatment. Proper pathway analysis uses survival analysis techniques (Kaplan-Meier curves for persistence, Cox proportional hazards for comparing treatments) that appropriately handle censored observations. Competing risks analysis is essential when patients can experience multiple mutually exclusive outcomes (e.g., switch to new therapy vs. discontinue all therapy vs. die).
Working with providers who offer epidemiologic expertise—not just data access—ensures these methodologic nuances are handled correctly. The gap between licensing claims data and extracting scientifically rigorous insights is substantial.
Getting Started with Treatment Pathway Analysis: A Strategic Approach
If you’re a VP of Market Access, Director of Commercial Analytics, or data science leader at a pharmaceutical company, here’s how to approach claims-based treatment pathway analysis strategically.
Define Requirements Before Evaluating Options
Don’t start by contacting data providers. Start by documenting what you need:
Coverage requirements: Which geographies, therapeutic areas, patient populations, and payer types must be represented? What minimum sample size do you need for statistical power?
Analytical capabilities: Will your team run analyses (requiring self-service platforms), or do you need full-service research support? What level of epidemiologic expertise do you have in-house?
Integration needs: Do you need claims data linked with EHR, lab, or specialty pharmacy data? What about API access for ongoing monitoring versus one-time studies?
Compliance constraints: What are your GDPR requirements? Do you need synthetic data for scenario modeling? What about data residency requirements?
Timeline and budget: When do you need insights (for HTA submissions, launch planning, etc.)? What’s your budget range for licensing and analytical support?
This clarity prevents costly mismatches between what providers offer and what you actually need. Most companies skip this step and waste months evaluating options that were never suitable.
Understand the Landscape Dimensions
The claims data market includes dozens of providers with overlapping but distinct capabilities. Key dimensions of variation include:
Data recency: Real-time vs. adjudicated claims (trading completeness for timeliness)
Geographic coverage: Pan-European vs. market-specific depth
Therapeutic specialization: Broad coverage vs. deep expertise in specific disease areas
Analytical tools: Self-service query platforms vs. full-service research teams vs. AI-powered predictive analytics
Cost models: Per-query pricing vs. annual licenses vs. project-based fees
Complementary data: Pure claims vs. claims linked with EHR, lab, or other sources
Understanding where your requirements sit on each dimension helps narrow the field to providers whose capabilities actually match your needs.
Leverage Expert Guidance for Vendor Selection
The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities.
Expert advisors who understand both your business objectives and the vendor landscape can accelerate your path to value while avoiding common pitfalls:
Avoiding capability mismatches: Licensing comprehensive pan-European data when you need deep market-specific insights (or vice versa) wastes budget and delays projects.
Preventing analytical bottlenecks: Self-service platforms are cost-effective if you have in-house epidemiologic expertise. Without it, they become expensive shelfware while you scramble to hire or outsource analysis.
Optimizing cost structures: Per-query pricing works for occasional studies. For ongoing competitive intelligence, annual licenses or full-service partnerships may offer better value.
Ensuring compliance: Not all “anonymized” data meets GDPR Article 9 requirements. Understanding which anonymization approaches actually protect you legally requires compliance expertise.
Navigating this landscape requires deep market knowledge that most companies lack internally. The difference between a well-matched data partnership and a costly mismatch often comes down to having guidance from professionals who know both the pharmaceutical industry and the evolving RWE ecosystem.
Pilot Before Scaling
Once you’ve identified suitable options, start with a focused pilot project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements.
A well-designed pilot should:
Test a specific research question central to your decision-making (not a hypothetical exercise)
Validate data quality and coverage for your therapeutic area
Assess the provider’s analytical capabilities and responsiveness
Confirm that insights are actionable for your commercial or market access teams
Evaluate time-to-insight against your business timelines
This de-risks larger investments and often reveals gaps between promised and delivered capabilities.
Plan for Integration and Iteration
Treatment pathway analysis rarely produces one-and-done insights. The most valuable applications involve ongoing competitive intelligence, continuous monitoring of launch performance, or iterative hypothesis testing.
Build flexibility into your approach:
Technical integration: Can claims data feed into your existing analytics infrastructure? What about API access for automated updates?
Team capabilities: Do you need to hire pharmacoepidemiologists, or can you access that expertise through your provider?
Iteration budget: Initial analyses often raise new questions. Reserve budget for follow-up studies that investigate unexpected findings.
Cross-functional alignment: Ensure commercial, market access, and medical affairs teams all understand how to leverage pathway insights in their workflows.
The pharmaceutical companies extracting maximum value from claims data aren’t those with the largest databases—they’re those with clear strategic objectives, well-matched capabilities, and processes for translating insights into action.
The Strategic Advantage of Real-World Treatment Pathway Intelligence
The pharmaceutical companies that win in increasingly competitive markets are those that understand not just whether their products work in trials, but how they perform in the messy reality of clinical practice.
Treatment pathway analysis using aggregated health insurance claims data provides that intelligence. It shows you where patients actually start treatment (not where guidelines say they should start). It reveals the persistence challenges that undermine forecasts. It exposes the switching patterns that determine competitive share. And it identifies the gaps in care where your product can deliver unique value.
This isn’t theoretical. Every major pharmaceutical company now incorporates claims-based pathway analyses into market access strategy, launch planning, and evidence generation. The ones doing it well—with robust data, rigorous methodology, and integration across commercial and medical functions—are the ones demonstrating value to payers, optimizing positioning, and achieving market access success.
For companies operating across Continental Europe specifically, understanding regional treatment variations, payer dynamics, and market-specific prescribing patterns requires data with appropriate geographic granularity and analytical sophistication.
Whether you’re preparing an HTA submission, planning a product launch, optimizing therapy positioning, or simply trying to understand why your forecasts missed by 40%, treatment pathway analysis using aggregated claims data provides the answers you need—grounded in what actually happens when physicians prescribe and patients fill medications in the real world.
The gap between understanding what claims data can do and successfully implementing pathway analysis in your organization requires expertise in pharmaceutical strategy, real-world evidence methodology, and the evolving vendor landscape. Most companies underestimate this gap and either delay critical projects or make costly data partnership decisions that don’t align with their actual needs.
Next Steps: Strategic Guidance for Treatment Pathway Analysis
Understanding treatment pathways through claims data isn’t just about accessing databases—it’s about matching the right analytical capabilities to your specific strategic objectives while navigating a complex and rapidly evolving vendor landscape.
At MEDDDICAL, we help pharmaceutical and MedTech companies develop real-world evidence strategies that actually work. We don’t sell data. We provide expert guidance on:
Requirements definition: Translating business questions into specific data and analytical requirements
Landscape navigation: Understanding which providers offer capabilities that match your needs across coverage, analytics, compliance, and cost dimensions
Partnership strategy: Structuring data relationships that deliver value without creating vendor lock-in or capability gaps
Implementation support: Ensuring your team can actually extract insights and translate them into commercial action
If you’re preparing for market access across European markets, need competitive intelligence on treatment patterns, or want to understand real-world persistence and switching for your therapeutic area, let’s discuss how to approach this strategically.
Schedule a consultation to explore how claims-based pathway analysis can support your specific objectives—and how to navigate the vendor landscape efficiently.
Learn about strategic approaches to real-world evidence that align data capabilities with business priorities rather than letting database features drive strategy.
Discover what to look for in claims data partnerships to avoid the common mismatches that delay projects and waste budget.
The difference between launching with assumptions versus launching with evidence is measurable. The difference between expensive database licenses that sit unused and strategic data partnerships that drive decisions is expert guidance on what you actually need—and how to get it.
Sources & References
- Berger ML, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003-1008. https://pubmed.ncbi.nlm.nih.gov/28913966/
- FDA. Framework for FDA’s Real-World Evidence Program. December 2018. https://www.fda.gov/media/120060/download
- FDA. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products. 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory
- Zhu R, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective. Clin Pharmacol Ther. 2023;114(2):292-308. https://pubmed.ncbi.nlm.nih.gov/37393555/
- Dang A. Real-World Evidence: A Primer. Pharmaceut Med. 2023;37(1):25-36. https://pubmed.ncbi.nlm.nih.gov/36604368/
- Blonde L, et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther. 2018;35(11):1763-1774. https://pubmed.ncbi.nlm.nih.gov/30357570/
- Murage MJ, et al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting. J Dermatolog Treat. 2019;30(2):141-149. https://pubmed.ncbi.nlm.nih.gov/30152785/
- Edgerton C, et al. Real-World Treatment and Care Patterns in Patients with Rheumatoid Arthritis Initiating First-Line Tumor Necrosis Factor Inhibitor Therapy in the United States. ACR Open Rheumatol. 2024;6(2):79-88. https://pubmed.ncbi.nlm.nih.gov/38093519/
- Birck MG, et al. Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020). Sci Rep. 2023;13:17739. https://www.nature.com/articles/s41598-023-44389-9
- Mathai SC, et al. Identifying patients with pulmonary arterial hypertension using administrative claims algorithms. Ann Am Thorac Soc. 2019;16(6):797-806. https://pubmed.ncbi.nlm.nih.gov/30821965/
- Galiè N, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. https://pubmed.ncbi.nlm.nih.gov/36017548/
- Benza RL, et al. Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States. Pulm Circ. 2022;12(3):e12122. https://pubmed.ncbi.nlm.nih.gov/35795357/
